Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investors Events
  • Pre market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
November 8, 2022 10:07 AM 2 min read

John Fetterman Vs. Dr. Oz: A Medical Professional Weighs In On Fetterman's Debate Performance And She's Fuming

by Maureen Meehan Benzinga Editor
Follow

Five months after Lt. Gov. John Fetterman’s stroke, which nearly killed him, PA's Democratic nominee for the US Senate – the results of which will shift the balance in said Senate – went toe-to-toe with multimillionaire TV host Dr. Oz in their first and only debate. As predicted, they disagreed over just about everything including hot-button issues like abortion, the economy, cannabis, healthcare, crime and a certain former Republican president who hovers over numerous midterm electoral campaigns.

While all of the above was roundly discussed, analyzed and picked over after Tuesday’s debate, most media reports led with commentary about Fetterman’s “halting speech,” “lingering effects from his stroke,” and “Fetterman’s struggle to effectively communicate.” Some even called Fetterman’s auditory issues “heartbreaking.” 

Fetterman, by the way, addressed the issue right at the beginning. “Let’s also talk about the elephant in the room: I had a stroke,” he said in his opening remarks, adding “He’ll never let me forget that.” He was referring to the various occasions when Oz mocked and goaded Fetterman for refusing to debate, which Fetterman said he'd do after he fully recovered his speech.

What Does An Expert Think About All This Stroke Talk? 

Kellin Squire is an emergency department nurse in Charlottesville who is running for a seat in the Virginian House of Delegates.

Referring to the wall-to-wall media coverage of Fetterman’s debate performance, Squire said that candidates like Dr. Oz who believe abortion should be between "a woman, her doctor, and local political leaders" (he really said that in the debate!) and who also bought a second mansion in a different state just to run for office, "are a dime a dozen. But a stroke victim who is doing better than most people would be in their predicament? WOO, LET'S BURN 'EM, FELLAS!"

Stroke In The U.S.

Stroke is a leading cause of death for Americans and leading cause of long-term disability. Every 40 seconds, someone in the U.S. has a stroke and every 3.5 minutes, someone dies of a stroke, according to the CDC.

Kellin told Daily Kos readers about a patient of hers who presented with expressive aphasia (partial loss of the ability to produce language) but never fully recovered. 

“And so, I have to tell you, to be doing as good as John Fetterman was doing last night is a huge win for any ER, ICU, or Neuro nurse watching.”

Meanwhile, Fetterman's campaign raised over a million dollars within hours after the debate ended.

Photo: Wikipedia

Original publication: 2022-10-26

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.


Posted In:
CannabisNewsPoliticsMarketsGeneralICYMIJohn Fetterman
Beat the Market With Our Free Pre-Market Newsletter
Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity Newsletter
Comments
Loading...